IPHYF (Innate Pharma) Common Stock: $5.49 Mil (As of Dec. 2025)


IPHYF Innate Pharma SA IPHYF
29 GF Score
Price $1.65
GF Value $0.14
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Innate Pharma Common Stock?

Innate Pharma IPHYF 29 Common Stock is $5.49 Mil as of Dec. 2025. GuruFocus rates IPHYF with a GF Score™ of 29/100 and a GF Value™ of $0.14 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Innate Pharma's quarterly common stock increased from Dec. 2024 ($4.39 Mil) to Jun. 2025 ($5.32 Mil) and increased from Jun. 2025 ($5.32 Mil) to Dec. 2025 ($5.49 Mil).

Innate Pharma's annual common stock declined from Dec. 2023 ($4.41 Mil) to Dec. 2024 ($4.39 Mil) but then increased from Dec. 2024 ($4.39 Mil) to Dec. 2025 ($5.49 Mil).

Innate Pharma Common Stock Historical Data

* Premium members only.

The historical data trend for Innate Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma Common Stock Chart

Innate Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.50 4.25 4.41 4.39 5.49

Innate Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.41 4.36 4.39 5.32 5.49
IPHYF
29GF Score
Innate Pharma SA IPHYF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innate Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $5.49 Mil mean?
Innate Pharma (IPHYF) has a Common Stock of $5.49 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Innate Pharma and its competitors.
Is Innate Pharma's Common Stock too high?
Innate Pharma's current Common Stock is $5.49 Mil. Overall, Innate Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Common Stock compare to VRTX and REGN?
Innate Pharma's Common Stock of $5.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Innate Pharma and its competitors. Innate Pharma's current Common Stock is $5.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.14, compared to a current price of $1.65 — trading 1078.6% above its estimated fair value. The current Common Stock is $5.49 Mil. Innate Pharma's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Innate Pharma (IPHYF), the current Common Stock is $5.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innate Pharma (IPHYF) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.65 is trading 1078.6% above its estimated GF Value™ of $0.14. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHYF:

  • Common Stock: $5.49 Mil
  • GF Value™: $0.14 vs. price of $1.65 (1078.6% above fair value)
  • GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the IPHYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
29GF Score

Get the complete analysis for IPHYF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$0.14
GF Value